ClinicalTrials.gov
ClinicalTrials.gov Menu

WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism (WAVe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03297359
Recruitment Status : Recruiting
First Posted : September 29, 2017
Last Update Posted : July 10, 2018
Sponsor:
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
Cancer patients that develop blood clots are treated with low molecular weight heparin injections (LMWH). One kind of these LMWHs, dalteparin, has its dose determined based on a patient's weight using a formula of 200 international units (IU) per kilogram (kg). The current dosing of dalteparin approved by Health Canada has a maximum daily dose of 18 000 IU/day which is weight-adjusted for patients up to 90 kg. Any patient weighing more than 90 kg would take the same dosage regardless of their weight. The aim of this study is to assess the safety of using weight-adjusted dalteparin in cancer-associated venous thromboembolism patients that weigh more than 90 kg.

Condition or disease Intervention/treatment Phase
Cancer Venous Thromboembolism Obesity Biological: Dalteparin Phase 2

Detailed Description:

The study is designed as a multicentre prospective cohort study with multiple Canadian sites. It will be initiated at The Ottawa Hospital prior to being offered externally. After obtaining informed consent, and confirming eligibility, participants weighing more than 90 kg with acute cancer-associated thrombosis will be treated with therapeutic weight-adjusted dalteparin (subcutaneous once daily injection, or twice daily, if the conditions of the participant do not allow once daily injection as per clinical judgement) beginning at enrolment (within 12 hours) and continuing until Day 30 visit. Subjects will receive therapeutic doses of dalteparin at a dose of approximately 200 IU/kg SC daily (up to 33,000 IU) for one month. Following this study period of 30 days (± 4 days), patients will be followed for 5 months. During the follow-up period, each patient will pursue his/her treatment as per usual standard treatment protocols provided at each institution. Treatment used and clinical outcomes will be collected at the end of the follow-up period.

The majority of Canadian Thrombosis specialists use weight adjusted dosing of dalteparin in patients weighing more than 90 kg with cancer-associated VTE. No expert recommends capping the dose of dalteparin to 18,000 IU in patients weighing over 90 kg as suggested by the product monograph. However, the risk of major bleeding episodes in patients over 90 kg receiving weight-adjusted LMWH remains unclear. The estimated rate of major bleeding episodes of patients with cancer associated VTE (Mean weight 79.1 kg) managed with therapeutic dose of dalteparin is 3.6% (95% CI: 1.9 to 6.2). We hypothesize that the rate of major bleeding events will be similar in patients (> 90 kg) with cancer-associated VTE treated with dalteparin 200 IU/kg daily (up to 32,500 IU). We plan to recruit 150 patients in this cohort study. We expect 6 major bleeding events. This would provide us with an overall bleeding event of 4% with an upper bound of the confidence interval of 8.5%). An informal survey of Canadian thrombosis expert has demonstrated that clinicians would feel reassured and continue to use weight-adjusted dalteparin in cancer patients weighing more than 90kg if the upper bound of the 95% confidence interval is less than 9% (i.e. < 3% possible absolute rate difference).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism
Actual Study Start Date : March 21, 2018
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Weight adjusted dalteparin

Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.

91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)

≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))

Biological: Dalteparin
daily subcutaneous injection of weight-adjusted dalteparin




Primary Outcome Measures :
  1. Major bleeding episode [ Time Frame: up to day 30 ]
    1. Fatal bleeding, and/or,
    2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or,
    3. Bleeding causing a fall in hemoglobin level of ≥20 g/L, or leading to transfusion of ≥2 units of whole blood or red cells.


Secondary Outcome Measures :
  1. Clinically relevant non major bleeding events [ Time Frame: up to day 30 ]

    As overt bleeding episodes not meeting the inclusion for major bleeding but associated with one of the following:

    9 CONFIDENTIAL and PROPRIETARY OHRI Protocol Version 1 - 30 AUG 2017

    1. Medical intervention,
    2. An unscheduled contact with a physician,
    3. Temporary cessation of anticoagulant treatment.

  2. Minor bleeding events [ Time Frame: up to day 30 ]
    Overt bleeding not meeting the major bleeding or clinically-relevant non-major bleeding definitions

  3. Recurrent VTE events [ Time Frame: Up to day 180 ]
    1. Recurrent deep vein thrombosis
    2. Recurrent Pulmonary embolism

  4. Overall mortality [ Time Frame: Up to day 180 ]
    Death

  5. Bioaccumulation of study drug [ Time Frame: Up to day 30 ]
    Trough anti-Xa level measuring > 0.4 IU/mL done at Day 7 & 30 follow-up visits.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Known pathologically-confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin),
  2. Confirmed symptomatic or incidental deep vein thrombosis requiring treatment, or confirmed symptomatic or incidental pulmonary embolism of a segmental or larger pulmonary artery,
  3. Weight > 90 kg,
  4. Age ≥18 years,
  5. Hemoglobin ≥ 80 g/L,
  6. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form.

Exclusion Criteria:

  1. Acute VTE managed with thrombectomy, insertion of an inferior vena cava filter or with the use of thrombolytic agents,
  2. More than 72 hours pre-treatment with therapeutic dosage of other LMWH, direct oral anticoagulants or vitamin K antagonists prior to enrolment to manage the current VTE event (unless the participant has been treated with weight-adjusted doses of commercial dalteparin in consistency with the dosing regime outlined in the protocol up to Day 7 visit [±2 days]),
  3. Contraindication to heparin therapy:

    1. history of heparin induced thrombocytopenia (HIT) as reported by patient,
    2. platelet count of less than 50 x 109/L,
    3. actively bleeding,
    4. reported history of severe uncontrolled hypertension,
    5. documented peptic ulcer within 6 weeks,
    6. reported history of severe hepatic failure,
    7. creatinine clearance of < 30 ml/min as calculated by the Cockcroft-Gault formula,
    8. heparin allergy,
    9. Other contraindication to anticoagulation.
  4. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or 4 at the time of study enrolment,
  5. Life expectancy < 1 month,
  6. Women of childbearing age without proper contraceptive measures and women who are pregnant or breast feeding,
  7. Participating in another interventional trial that may result in co-intervention or contamination (to be determined by sponsor),
  8. Unable/unwilling to provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03297359


Contacts
Contact: Yan He, MSc (613) 737-8899 ext 72103 yahe@ohri.ca

Locations
Canada, Alberta
Alberta Health Services Not yet recruiting
Edmonton, Alberta, Canada, T6G 2V2
Contact: Yan He, MSc         
Canada, Nova Scotia
Nova Scotia Health Authority Not yet recruiting
Halifax, Nova Scotia, Canada, B3H 1V7
Contact: Yan He, MSc         
Canada, Ontario
The Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Yan He, MSc         
Principal Investigator: Marc Carrier, MD         
Toronto General Hopsital Not yet recruiting
Toronto, Ontario, Canada, M5G 1J6
Contact: Yan He, MSc         
Sunnybrook Hospital Not yet recruiting
Toronto, Ontario, Canada
Contact: Yan He, MSc         
Canada, Quebec
McGill University Health Center Not yet recruiting
Montréal, Quebec, Canada, H4A 3J1
Contact: Yan He, MSc         
Sponsors and Collaborators
Ottawa Hospital Research Institute
Investigators
Principal Investigator: Marc Carrier, MD Ottawa Hospital Research Institute

Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT03297359     History of Changes
Other Study ID Numbers: CTO - 0923
First Posted: September 29, 2017    Key Record Dates
Last Update Posted: July 10, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Ottawa Hospital Research Institute:
Dalteparin
Fragmin

Additional relevant MeSH terms:
Thromboembolism
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Dalteparin
Heparin, Low-Molecular-Weight
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action